Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963034 · ClinicalTrials.gov registry record · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
- 20
- Study locations
NCT06963034: Recruiting Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.
NCT06963034 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 284 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06963034, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NBI-1117568
Study Locations (20)
California
- Neurocrine Clinical Site - Anaheim
- Neurocrine Clinical Site - Pico Rivera
- Neurocrine Clinical Site - San Diego
- Neurocrine Clinical Site - Sherman Oaks
- Neurocrine Clinical Site - Torrance
Georgia
- Neurocrine Clinical Site - Atlanta
- Neurocrine Clinical Site - Decatur
- Neurocrine Clinical Site - Snellville
Arkansas
- Neurocrine Clinical Site - Bryant
- Neurocrine Clinical Site - Little Rock
Florida
- Neurocrine Clinical Site - Hollywood
- Neurocrine Clinical Site - Miami Lakes
New York
- Neurocrine Clinical Site - Staten Island
- Neurocrine Clinical Site - The Bronx
Texas
- Neurocrine Clinical Site - Austin
- Neurocrine Clinical Site - DeSoto
Illinois
- Neurocrine Clinical Site - Chicago
Maryland
- Neurocrine Clinical Site - Gaithersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
What NCT06963034 shows while recruiting
NCT06963034 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06963034 names 20 study sites across 10 states, led by California, Georgia, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06963034 about?
NCT06963034 is a clinical study titled "NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia". The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
What is the current status of trial NCT06963034?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2025-05-08. Estimated completion is 2027-10.
What conditions does trial NCT06963034 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06963034?
The interventions under investigation include: Placebo (DRUG), NBI-1117568 (DRUG).
Who is sponsoring clinical trial NCT06963034?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963034 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06963034's enrollment target sits among peer trials
284 66th of 315 higher than 249 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT07227636 · 284 participants · Phase 2
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI